Ptc Therapeutics (PTCT) Operating Leases (2019 - 2026)

Ptc Therapeutics' Operating Leases history runs 8 years deep, the most recent figure standing at $87.5 million for Q2 2026.

• In Q2 2026, Operating Leases rose 5.51% year-over-year to $87.5 million; the TTM figure through Jun 2026 stood at $87.5 million (up 5.51% YoY), while the FY2025 annual figure was $93.6 million, up 24.87% from the prior year.
• Operating Leases for Q2 2026 stood at $87.5 million, down from $90.1 million in the prior quarter.
• The five-year high for Operating Leases was $146.3 million in Q2 2022, with the low at $74.9 million in Q4 2024.
• The 5-year median for Operating Leases is $97.3 million (2023), against an average of $99.9 million.
• The sharpest annual moves came in 2022 and 2025: Operating Leases surged 91.37% in 2022, then retreated 28.8% in 2025.
• Ptc Therapeutics' Operating Leases stood at $100.9 million in 2022, then decreased by 3.21% to $97.6 million in 2023, then declined by 23.23% to $74.9 million in 2024, then gained by 24.87% to $93.6 million in 2025, then decreased by 6.46% to $87.5 million in 2026.
• Business Quant data shows PTCT's Operating Leases at $87.5 million in Q2 2026, $90.1 million in Q1 2026, and $93.6 million in Q4 2025.